[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100369403":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":38,"responsibleParty":57,"collaborators":25,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":25,"overallStatus":78,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Institute of Liver and Biliary Sciences, India","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PARTO\u002FBRTO + SMT","EXPERIMENTAL","PARTO\u002FBRTO with SMT will be given.",[13],"Procedure: Plug assisted retrograde transvenous obliteration\u002FBalloon-occluded retrograde transvenous obliteration",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Medical Treatment","ACTIVE_COMPARATOR","Antibiotics, nutrition and supportive treatment",[19],"Other: Standard Medical Treatment",[21,26],{"type":22,"name":23,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Plug assisted retrograde transvenous obliteration\u002FBalloon-occluded retrograde transvenous obliteration",[9],null,{"type":6,"name":15,"description":17,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":31,"role":32},"Dr Shiv Kumar Sarin, DM","Institute of Liver and Biliary Sciences","PRINCIPAL_INVESTIGATOR",[34],{"name":30,"role":35,"phone":36,"phoneExt":25,"email":37},"CONTACT","01146300000","shivsarin@gmail.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Institute of Liver & Biliary Sciences","RECRUITING","New Delhi","National Capital Territory of Delhi","110070","India","IN",{"type":48,"coordinates":49},"Point",[50,51],77.2148,28.62137,{"lat":51,"lon":50},[54],{"name":55,"role":35,"phone":36,"phoneExt":25,"email":56},"Dr Rakesh Kumar Jagdish, MD","dr.rkj.kapil@gmail.com",{"type":58,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100369403","to-study-the-impact-of-balloon-occluded-retrograde-transvenous-obliteration-brtoplug-assisted-retrograde-transvenous-obliteration-parto-mediated-portal-flow-modulation-in-reduction-of-ammonia-and-improvement-in-organ-volume-and-functionality-in-patients-of-cirrhosis-with-lr-shunt-100369403",false,"NCT04089878","\"To Study the Impact of Balloon-occluded Retrograde Transvenous Obliteration (BRTO)\u002FPlug Assisted Retrograde Transvenous Obliteration (PARTO) Mediated Portal Flow Modulation in Reduction of Ammonia and Improvement in Organ Volume and Functionality in Patients of Cirrhosis With LR Shunt","\"To Study the Impact of Balloon-occluded Retrograde Transvenous Obliteration (BRTO)\u002FPlug Assisted Retrograde Transvenous Obliteration (PARTO) Mediated Portal Flow Modulation in Reduction of Ammonia and Improvement in Organ Volume and Functionality in Patients of Cirrhosis With LR Shunt - A Randomized Trial.ImPARTO Trial\"","Inclusion Criteria:\n\n* Child A and B cirrhotic patients with Gastro\u002Flieno-renal shunt of \\>8 mm.\n* Covert or Overt HE\n* Age 18 to 70 years\n\nExclusion Criteria:\n\n* Intractable ascites\n* PVT (with 100 % block )or PV Cavernoma and splenic vein thrombosis\n* High risk esophageal varices (till eradicated)\n* HVPG \\>16 mm Hg\n* HCC\n* Pregnancy and lactation\n* Refusal to participate in the study","ALL","18 Years","70 Years",{"count":70,"type":71},50,"ESTIMATED","INTERVENTIONAL",[74],"NA","The informed consent will be obtained from the participants in the study. The study will be conducted on indoor patients, Department of Hepatology ILBS, New Delhi. This will be a Pilot study (sample size 25 cases in each arm) with 50% chances of each patient to randomized into each arm(1:1 randomization) .\n\nStudy Population - Patients with hepatic encephalopathy with LR shunt admitted in wards\u002FHDU (High Dependency Unit)\u002FLC ICU(Liver Coma ICU).\n\nStudy design-Randomized controlled Trial\n\nStudy period- 1 year.\n\nSample Size-Single Centre prospective RCT\n\n* Sample size- Pilot study (sample size 25 cases in each arm)\n* Follow up duration-6 months",[77],"Liver Cirrhoses","UNKNOWN","2019-11-09",{"date":81,"type":82},"2019-11-13","ACTUAL",{"date":84,"type":82},"2019-09-14",{"date":86,"type":71},"2020-09-30",{"name":5,"class":6},1]